-+ 0.00%
-+ 0.00%
-+ 0.00%

Elevara Medicines raises $70 million Series A led by Sofinnova Partners, Forbion

PUBT·07/14/2026 11:00:46
Listen to the news
Elevara Medicines raises $70 million Series A led by Sofinnova Partners, Forbion
  • Elevara Medicines raised a USD 70 million Series A in October 2025 led by Forbion and Sofinnova Partners.
  • London-based, clinical-stage biotech developing therapies for rheumatoid arthritis and other chronic inflammatory diseases.
  • Proceeds earmarked for clinical development of lead candidate ELV001, an oral CDK4/6 inhibitor targeting synovial fibroblasts.
  • Phase 2b START-SYNERGY trial began in March 2026 with 180 patients; primary endpoint is change in DAS28-CRP at week 12.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sofinnova Partners SAS published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.